Radiation Necrosis

Disease

Related News

Precision Oncology Extends Survival for Lung Cancer Brain Metastases

Precision oncology has transformed brain metastases treatment from lung cancer, extending survival from 6-12 months to 3-5 years through targeted therapies, immunotherapy, and radiosurgery. With 100,000-200,000 annual cases in the US, multidisciplinary approaches now manage this once-terminal condition as a chronic disease.

Related Clinical Trials

NCT ID Title Status Phase
NCT07767981

Microbiome Determinants of Adverse Effects of Stereotactic Radiosurgery

RECRUITING
NCT07680127

TENS of Auricular Vagal Nerve for Radiation Necrosis

NOT_YET_RECRUITING NA
NCT07632092

Early [18F]-FDG PET Dynamic Analysis in Brain Metastases After Radiotherapy.

RECRUITING
NCT07422168

Hyperbaric Oxygen Therapy for Treatment of Severe Radiation-Induced Complications

COMPLETED NA
NCT06888817

Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

RECRUITING PHASE3
NCT05762172

Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis

COMPLETED NA
NCT05124912

REMASTer: REcurrent Brain Metastases After SRS Trial

RECRUITING NA
NCT02819479

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

COMPLETED PHASE2
NCT02212964

Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*

COMPLETED
NCT01651078

Laser Ablation After Stereotactic Radiosurgery

COMPLETED